Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 19;204:105365. doi: 10.1016/j.antiviral.2022.105365

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Effect of bergamottin on SARS-CoV-2 infection. (A) The antiviral effects of bergamottin against SARS-CoV-2 in Caco-2 cells. IFA assay showing the SARS-CoV-2 NP (green) and nuclei (blue) were displayed. 50 μM camostat was used as positive control. (B) Dose-response curves and table of IC₅₀ values of bergamottin for inhibition of SARS-CoV-2 and SARS-CoV-2 variants (B.1.1.7 and B.1.351). Drug cytotoxicity was determined by CCK-8 assay. Data represents mean ± SD for n = 3 biological replicates.